To include your compound in the COVID-19 Resource Center, submit it here.

FDA issues draft guidance on NSCLC endpoints

FDA issued draft guidance stating that the agency considers overall survival (OS) to be the standard clinical benefit endpoint

Read the full 197 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE